Explore the words cloud of the mABSPN project. It provides you a very rough idea of what is the project "mABSPN" about.
The following table provides information about the project.
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
|Coordinator Country||Netherlands [NL]|
|Total cost||165˙598 €|
|EC max contribution||165˙598 € (100%)|
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
|Duration (year-month-day)||from 2018-06-15 to 2020-06-14|
Take a look of project's partnership.
|1||UNIVERSITAIR MEDISCH CENTRUM UTRECHT||NL (UTRECHT)||coordinator||165˙598.00|
The pneumococcus (Streptococcus pneumoniae) is the predominant cause of community-acquired pneumonia and causes otitis media, sinusitis, meningitis and sepsis. The increased serotype replacement and antibiotic resistance, reinforces the necessity of developing alternative treatment strategies for this pathogen. Monoclonal antibodies that boost the host immune system are attractive candidates to fight the high rates of morbidity and mortality due to this important human pathogen. Antibodies recognizing bacterial surface structures could be used to trigger activation of the complement cascade and subsequent bacterial killing. However, no significant progress has been made in the direction of immune system boosting therapies against pneumococci, mainly caused by our limited insights into antibody-driven immune activation on bacteria. With this proposal, I aim to study whether complement-enhancing monoclonal antibodies can be used as treatment against pneumococci. Through a combination of advanced sequencing approaches and functional complement activation assays, I will first identify antibodies against S. pneumoniae driving potent complement activation. Then I will use my expertise in S. pneumoniae infection models to unravel whether monoclonal antibodies eliciting complement are effective in pneumococcal killing in vitro and in vivo. The work proposed represents a first systematic approach to design effective therapeutic antibodies against S. pneumoniae that function via enhanced complement activation. Altogether, a better understanding of antibody-dependent complement activation on bacteria will create new avenues for the design of new therapeutic strategies to improve both antibody therapies and vaccination strategies in diseases caused by pathogenic bacteria.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MABSPN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MABSPN" are provided by the European Opendata Portal: CORDIS opendata.
Diagnosis, prediction, communication and rehabilitation for patients with disorders of consciousnessRead More
A self-esteem process framework of the transition to workRead More
Wired: The Role of Infrastructure in the Tibetan Buddhist Revival in Contemporary ChinaRead More